COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (2022)

COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (1)

Le nombre de tests positifs et d’entrées à l’hôpital pour COVID-19 continue d’augmenter, en particulier chez les personnes non vaccinées (illustration).

Par David Paitraud - Date de publication : 14 Décembre 2021

La DREES* a publié une analyse des données de contamination et d'hospitalisation associée à la COVID-19. Elle révèle une sur-représentation des personnes non vaccinées parmi les personnes testées positives, et parmi celles hospitalisées.

*Direction de la recherche, des études, de l'évaluation et des statistiques

(Video) Découverte | Les vaccins contre la COVID-19 sont-ils efficaces?

Résumé
La Direction de la recherche, des études, de l'évaluation et des statistiques (DREES) publie une analyse des données appariées issues des bases SI-VIC (traçabilité des hospitalisations pour COVID-19), SI-DEP (traçabilité des tests de dépistage COVID-19) et VAC-SI (traçabilité de la vaccination contre la COVID-19), recueillies entre le 31 maiet le 28 novembre 2021.

Cette analyse de données en vie réelle montrent :

  • une surreprésentation des personnes non vaccinées parmi les personnes testées positives au COVID-19,
  • une surreprésentation encore plus marquée des personnes non vaccinées parmi les personnes hospitalisées,
  • l'érosion de la protection vaccinale après quelques mois (en termes d'infections symptomatiques) et l'intérêt de la dose de rappel pour protéger contre la COVID-19 (infections symptomatiques et hospitalisations),
  • l'impact de l'âge chez les non-vaccinés, avec un risque majoré d'hospitalisation chez les séniors non vaccinés (60 ans et plus).

L'analyse publiée le 10 décembre 2021 par la Dreesrepose sur un appariement des données recueillies entre le 31 mai et le 28 novembre 2021 (extraction le 30 novembre 2021) et provenant des bases françaises suivantes :

  • SI-VIC (Système d'Information pour le suivi des VICtimes d'attentats et de situations sanitaires exceptionnelles), dont sont issues les données sur les hospitalisation conventionnelles ou en soins critiques (réanimation, soins intensifs, soins continus) de patients hospitalisés pour ou positifs au test COVID-19,
  • SI-DEP (Système d'Informations de DEPistage), permettant de disposer des données sur les résultats des tests de dépistage du SARS-CoV-2,
  • VAC-SI (Système d'Information VACcin COVID), correspondant à la base de données sur les vaccinations COVID-19.

Une analyse pour évaluer la relation entre statut vaccinal et développement/évolution de la maladie COVID-19
Cette analyse s'inscrit dans le cadre d'un suivihebdomadaire réalisé par la Drees.
L'objectif principal estd'évaluer la relation entre :

(Video) Les effets indésirables des vaccins contre le covid-19 : auditions au Sénat

  • le statut vaccinal (non vacciné ou vacciné, en distinguant le niveau de vaccination) ;
  • et l'enregistrement d'un test positif de dépistage COVID-19 ou d'une hospitalisation pour COVID-19 (conventionnelle ou en soins critiques).

Tests positifs et hospitalisation : sur-représentation des personnes non vaccinées
L'analyse de la Drees montre unesur-représentation des personnes non vaccinées parmi :

  • les personnes testées (ce phénomène s'explique par la nécessité de réaliser un test pour valider le passe sanitaire),
  • les personnes dont le test RT-PCR est positif, ce qui sous-entend un risque accru de contamination dans cette sous-population,
  • les personnes positives développant des symptômes,
  • lespersonnes hospitalisées, pour lesquelles un test PCR positif a été identifié.

Entre le 1er et le 28 novembre 2021, les 9 % de personnes non vaccinées dans la population française de 20 ans et plus représentent :

  • près de 26 % des tests PCR positifs chez les personnes symptomatiques,
  • 40 % des admissions en hospitalisation conventionnelle,
  • 51 % des entrées en soins critiques,
  • 39 % des décès pour COVID-19.

Ces données montrent que la sous-population des personnes non vaccinées (plus de 20 ans),bien que minoritaire (9 %),concentre une proportion importante des événements liés à l'épidémie de COVID-19, que ce soit en termes de contamination, de symptômes ou de progression vers une forme nécessitant une prise en charge plus lourde (cf. Figure 1).

Figure 1 -Répartition de la population, des tests PCR, des entrées hospitalières et des décès selon le statut vaccinal pour les personnes de 20 ans et plus (1)
COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (2)

COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (3)
(1) source : appariement SI-VIC, SI-DEP, VAC-SI ; populations Insee estimées au 1er janvier 2021. Calculs DREES. Données extraites le 7 décembre 2021 pour la période du 1 er novembre au 28 novembre 2021.


Analyse à taille de population comparable : les données rapportées sur un dénominateur commun (pour 100 000 personnes)
En pleine cinquième vague épidémique de COVID-19, les chiffres bruts issus des bases de données montrent une augmentation globale du nombre de tests pratiqués et d'hospitalisations quel que soit le statut vaccinal.

Pour affiner leur analyse et afin de comparer les sous-populations entre elles (vaccinés versus non vaccinés), les auteurs ont rapporté les données (2) d'événements liés au COVID-19 (tests positifs, hospitalisations, décès) à taille de population comparable (pour 100 000 personnes ou 1 million de personnes). Dans toutes les catégories d'événements, la population des non vaccinés est sur-représentée (cf. Tableau I) :

  • nombre de RT-PCR positifs : plus de 1 300 pour 100 000 non vaccinés (dont 700 symptomatiques) contre moins de 600 pour 100 000 personnes vaccinées (quel que soit le niveau de vaccination, avec au moins une injection), et environ 120 pour 100 000 personnes vaccinées depuis plus de 6 mois avec rappel ;
  • soins critiques : 233 personnes pour 1 million de personnes non vaccinées contre 13 personnes pour 1 million de personnes complètement vaccinées avec rappel ;
  • décès : 83 décès pour 1 million de personnes non vaccinées contre 13 personnes pour 1 million de personnes complètement vaccinées avec rappel.

Tableau I -Parts et nombres à taille de population comparable de tests et d'événements hospitaliers selon le statut vaccinal entre le 1 er et le 28 novembre 2021
COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (4)

(Video) Covid-19 - vaccin AstraZeneca : prudence ou emballement ?

(2) Sources : Appariement SI-VIC, SI-DEP, VAC-SI ; populations Insee estimées au 1er janvier 2021. Calculs DREES. Données extraites le 7 décembre 2021.


Des niveaux de protection variables en fonction du niveau de vaccination (niveau d'avancée dans le schéma de vaccination)
Les auteurs ont également évalué la protection vaccinale en fonction du niveau de vaccination, c'est-à-dire en distinguant différents états de vaccination parmi les personnes vaccinées :

  • partiellement vacciné,
  • complètement vacciné,
  • de moins de 3 mois, sans rappel,
  • de 3 à 6 mois, sans rappel,
  • de plus de 6 mois, sans rappel,
  • complètement vacciné avec rappel.

D'une façon générale, quel que soit l'état d'avancée du schéma vaccinal, les données montrent que la vaccination protège contre les formes symptomatiques et les entrées hospitalières, en comparaison à la sous-population des personnes non vaccinées qui enregistre des niveaux plus élevés.

En outre, au sein de la population des personnes vaccinées, l'analyse confirme la cinétique de la protection vaccinale au fil du temps, caractérisée par une érosion, et l'intérêt de la dose de rappel pour remonter le niveau de protection après 6 mois (pour les adultes de 20 ans et plus) :

  • la protection vaccinale du schéma complet est élevée durant les premiers mois pour toutes les classes d'âge, pour limiter les hospitalisations (conventionnelles ou en soins critiques) et lesinfections symptomatiques. Cette protection est comprise respectivement entre 90 et 95 % (sauf pour les 80 ans et plus où elle avoisine 85 %), et entre 80 et 85 % pour toutes les classes d'âge (protection contre les formes symptomatiques) ;
  • laprotection vaccinale contre le risque d'hospitalisation s'atténue légèrement au fil du temps après l'obtention du schéma complet, surtout pour les seniors, moins pour les personnes de 20 à 60 ans ;
  • la protection vaccinale s'érode beaucoup plus vis-à-vis des infections symptomatiques, pour toutes les classes d'âge, perdant entre 20 et 30 points entre les personnes vaccinées depuis moins de 3 mois et celles vaccinées depuis plus de 6 mois sans rappel. Pour ces derniers, la protection vaccinale contre les formes symptomatiques est estimée à environ 50 % ;
  • l'injection du rappel pour les personnes de plus de 60 ans dont le statut complet remonte à plus de 6 mois améliore la protection vaccinale à plus de 90 %, pour les infections symptomatiques comme pour les hospitalisations. Les bénéfices sont meilleurs que ceux obtenus avec la primo-vaccination.

Non vacciné plus âge avancé : des chiffres éloquents
L'âge avancé (à partir de 60 ans) est considéré depuis le début de la pandémie comme un facteur de risque majeur de forme grave de COVID. Cumulé avec l'absence de vaccination, ce facteur de risque est confirmé en termes d'hospitalisation, en comparaison à une population vaccinée
(cf.Figure 2).

Au sein de la population vaccinée de 60 à 80 ans, des différences sont également observées entre les personnes ayant reçu un rappel et les autres. Les premières sont moins représentées dans les événements liés à la COVID-19, soulignant l'intérêt de la dose de rappel.


Figure 2 - Nombre de tests PCR et d'événements hospitaliers à taille de population comparable par statut vaccinal pour les personnes de 60 à 79 ans et de 80 ans et plus (3)
COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (5)

COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (6)

(Video) Covid-19 : vers un remède ?

COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (7)

(3)Sources : Appariement SI-VIC, SI-DEP, VAC-SI ; populations Insee estimées au 1er janvier 2021. Calculs DREES. Données extraites le 8 décembre 2021 pour la période du 1er novembre au 28 novembre 2021


Enfin, dans la sous-population des non vaccinés, deux phénomènes associés à l'âge peuvent être observés (cf. Figure 3) :

  • les adultes non vaccinés de moins de 40 ans présentent un risque accru de test RT-PCR positif symptomatique. En comparaison aux autres personnes non vaccinées, ce risque est supérieur de 50 %. L'intensité des interactions sociales pour les jeunes adultes pourrait expliquer cette tendance ;
  • concernant le risque d'hospitalisation parmi les personnes non vaccinées, il croît avec l'âge ; en comparaison aux autres personnes non vaccinées, le risque d'hospitalisation en soins critiques est multiplié par 2 chez les 60 - 79 ans. Quant au risque d'hospitalisation conventionnelle, il est maximal chez les 80 ans et plus.

Figure 3 - Risques relatifs de test positif symptomatique et d'hospitalisation selon l'âge chez les non vaccinés

COVID19 et vaccination : analyse des données de contamination et d'hospitalisation (8)

Sources : Appariement SI-VIC, SI-DEP, VAC-SI. Modélisation DREES à partir des observations du 31 mai 2021 au 28 novembre 2021. Tests positifs avec symptômes indiqués par le patient.


Pour aller plus loin
Appariements entre les bases SI-VIC, SI-DEP et VAC-SI jusqu'au 28 novembre 2021 : le nombre de tests positifs et d'entrées à l'hôpital pour Covid-19 continue d'augmenter, en particulier chez les personnes non vaccinées (DREES, 10 décembre 2021)

FAQs

Can you get infected with COVID-19 after the vaccination? ›

COVID-19 vaccines also help protect against infection. People who are vaccinated may still get COVID-19.

What is the most effective vaccine for Covid? ›

A Pfizer-BioNTech or Moderna mRNA booster is preferred in most situations. (Only Pfizer boosters are authorized for children and teenagers.) Adults ages 50 and older should get a second booster four months after the first. In August 2022, the FDA authorized a bivalent Moderna shot for adults 18 and older.

Which vaccine is the most effective against the Delta variant? ›

COVID-19 vaccines are effective at preventing hospitalizations and emergency department visits caused by the Delta variant, according to data from a national study. That data also indicate that Moderna's vaccine is significantly more effective against Delta than Pfizer and Johnson & Johnson.

Is the COVID-19 Vaccine a pathogen? ›

All vaccines work by teaching our immune system to recognize a pathogen – a disease-causing organism. In the case of COVID-19 vaccines, this pathogen is the SARS-CoV-2 virus.

How long does immunity last after COVID vaccine? ›

Earlier research from the CDC suggested that protection from the Pfizer and Moderna COVID-19 vaccines could start to fade around 4 months after a booster dose. Protection against COVID-19 hospital stays seemed to drop from 91% soon after receiving a booster dose to 78% at the 4-month mark.

Can you get COVID twice? ›

Reinfection with the virus that causes COVID-19 means a person was infected, recovered, and then later became infected again. After recovering from COVID-19, most individuals will have some protection from repeat infections. However, reinfections do occur after COVID-19.

Which Covid vaccine is safest? ›

The Pfizer and Moderna vaccines are strongly recommended as safe and effective at preventing serious illness or death from COVID-19.

Which vaccine is most effective against Omicron? ›

"Based on the data supporting their authorizations, the bivalent COVID-19 vaccines are expected to provide increased protection against the currently circulating omicron variant," says Dr.

What is the most successful vaccine? ›

Smallpox vaccination with vaccinia virus is the most famous example of a highly effective vaccine and at the time when people were faced with smallpox outbreaks, this vaccine was associated with each of these characteristics that led to the implementation of a successful vaccine.

What is the best COVID shot for seniors? ›

U.S. adults aged 65 years or older who have been fully vaccinated with Pfizer-BioNTech or Moderna's COVID-19 vaccines are 94% less likely to be hospitalized with the disease than seniors who were not vaccinated, according to real-world evidence unveiled today by the U.S. Centers for Disease Control and Prevention (CDC) ...

How effective is the COVID vaccine against Omicron? ›

In a large cohort of nursing home residents, receipt of a second mRNA COVID-19 booster dose during circulation of SARS-CoV-2 Omicron subvariants was 74% effective at 60 days against severe COVID-19–related outcomes (including hospitalization or death) and 90% against death alone compared with receipt of a single ...

How long does COVID last? ›

Most people who test positive with any variant of COVID-19 typically experience some symptoms for a couple weeks. People who have long COVID-19 symptoms can experience health problems for four or more weeks after first being infected, according to the CDC.

How long do COVID antibodies last? ›

A UCLA study shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 — the virus that causes the disease — drop sharply over the first three months after infection, decreasing by roughly half every 36 days. If sustained at that rate, the antibodies would disappear within about a year.

How do vaccines protect us? ›

Vaccines help your immune system fight infections faster and more effectively. When you get a vaccine, it sparks your immune response, helping your body fight off and remember the germ so it can attack it if the germ ever invades again.

Do you get T cells from COVID vaccine? ›

But with all types of vaccines, the body is left with a supply of “memory” T-lymphocytes as well as B-lymphocytes that will remember how to fight that virus in the future. It typically takes a few weeks after vaccination for the body to produce T-lymphocytes and B-lymphocytes.

What is natural immunity? ›

Natural immunity: Immunity that is naturally existing, Natural immunity does not require prior sensitization to an antigen.

How long does the booster vaccine last? ›

How long does the booster last, and how effective is it? The UK Health Security Agency (UKHSA) published research in July 2022 that suggests that even six months after a booster vaccine, most people can expect a high degree of protection (about 80% vaccine effectiveness) from becoming seriously ill from Covid-19.

Should I get vaccinated if I have already had COVID-19? ›

Yes, you can and should get the vaccine if you previously were infected with the COVID-19 virus. The CDC recommends you get vaccinated even if you have already had COVID-19 because you can catch it more than once.

How long will I test positive? ›

You may continue to test positive on antigen tests for a few weeks after your initial positive. You may continue to test positive on NAATs for up to 90 days. Reinfections can occur within 90 days, which can make it hard to know if a positive test indicates a new infection.

How quickly can you test positive for Covid? ›

Your body takes one to three weeks after you have acquired the infection to develop antibodies to this virus. For this reason, serologic tests are not sensitive enough to accurately diagnose an active COVID-19 infection, even in people with symptoms.

Does Omicron infection protect against reinfection? ›

The relative protection of prior infection against reinfection with Omicron is 56% compared with 92% for the Delta variant. However, the population-level risk of reinfection with Omicron has not been described.

Which COVID vaccine is best for over 65? ›

Getting vaccinated prevents severe illness, hospitalizations and death. People 65 and older who received both doses of either Pfizer or Moderna vaccines showed a 94% reduced risk of COVID-19 related hospitalization.

What happens if I only get one COVID vaccine? ›

If you skip your second shot, the short answer is that you aren't getting the best protection from the two-dose series. All of the clinical trial data that measured effectiveness is based on people getting both doses. So, we don't know the level of protection you'll get from only one shot.

What is long COVID? ›

People with post-COVID conditions (or long COVID) may experience many symptoms. People with post-COVID conditions can have a wide range of symptoms that can last more than four weeks or even months after infection. Sometimes the symptoms can even go away or come back again.

Is there a vaccine for Omicron variant? ›

The U.S. Food and Drug Administration (FDA) has authorized the Moderna and Pfizer-BioNTech updated vaccines that target the original COVID-19 viral strain and two Omicron variants (BA. 4/BA.

What is the Covid Omicron symptoms? ›

Compared to other SARS-CoV-2 variants, the Omicron variant is associated with generally less severe symptoms that may include fatigue, cough, headache, sore throat or a runny nose. “Our study findings add to evidence that undiagnosed infections can increase transmission of the virus,” said Sandy Y.

Which vaccine is better Johnson and Johnson or Pfizer? ›

Both the Pfizer and J&J vaccines work, and are safe

Both the Pfizer and J&J vaccines are safe and effective in protecting people from severe illness and death from a COVID-19 infection. You can find more clinically-verified information about COVID-19 and vaccines on Discovery's COVID-19 information hub here.

What are five importance of vaccination? ›

Serious diseases like rubella, polio, tetanus, etc are preventable, saving people from the painful process of treatment and huge medical bills. It is prudent to get vaccinated early on and prevent contracting such diseases. Protection against several diseases also increases the life expectancy of individuals.

Who discovered vaccination? ›

The smallpox vaccine, introduced by Edward Jenner in 1796, was the first successful vaccine to be developed. He observed that milkmaids who previously had caught cowpox did not catch smallpox and showed that inoculated vaccinia protected against inoculated variola virus.

Which diseases can be prevented by vaccination? ›

  • Polio. Polio is a crippling and potentially deadly infectious disease that is caused by poliovirus. ...
  • Tetanus. Tetanus causes painful muscle stiffness and lockjaw and can be fatal. ...
  • The Flu (Influenza) ...
  • Hepatitis B. ...
  • Hepatitis A. ...
  • Rubella. ...
  • Hib. ...
  • Measles.
15 Sept 2022

What vaccines should a 70 year old have? ›

Most people get vaccinated as children, but you also need booster shots as you get older to stay protected against these diseases. The CDC recommends that adults get a Tdap (tetanus, diphtheria, and pertussis) or Td (tetanus, diphtheria) booster shot every 10 years.

Is there a 3rd booster shot for COVID? ›

A third dose is for people who are moderately or severely immune-compromised; their initial immune response from the first 2 doses may not have been strong enough, so a third dose is recommended as part of their primary vaccine series.

What does COVID sore throat feel like? ›

A sore throat could range from feelings of scratchiness to severe pain. Some people say a COVID sore throat feels like allergies. Others say it is like having strep throat.

What is vaccine effectiveness? ›

Vaccine effectiveness is a measure of how well vaccination protects people against outcomes such as infection, symptomatic illness, hospitalization, and death.

What is Covid incubation period Omicron? ›

The incubation period of the original, wild-type COVID-19 strain was 6.65 days, while the Omicron variant's incubation period has shortened to 3.42 days.

Which is most effective Moderna or Pfizer? ›

In adults, their initial efficacy estimates were virtually identical — 95% for Pfizer's vaccine, 94% for Moderna's. They were issued emergency use authorizations by the Food and Drug Administration within a week of each other in the United States in December 2020.

How long is Omicron contagious? ›

“There is not data to support five days or anything shorter than ten days [of isolation].” Barczak's own research, published on the medRxiv preprint server, suggests that one-quarter of people who have caught the Omicron variant of SARS-CoV-2 could still be infectious after eight days1.

What are Omicron symptoms if vaccinated? ›

What are the symptoms of Omicron? Symptoms of Omicron can be similar to the original COVID-19 virus and other variants, which can include a combination of the following: fever, cough, congestion, runny nose, headache, sore throat, muscle pains/aches and fatigue.

How do you know if your cough is a COVID cough? ›

a new, continuous cough – this means coughing a lot for more than an hour, or 3 or more coughing episodes in 24 hours. a loss or change to your sense of smell or taste. shortness of breath.

Do you build antibodies after having Covid? ›

After having COVID-19, most people's bodies develop antibodies to help fight it off. These are special molecules made by the body's disease defense system, the immune system. A study found that people with these antibodies were less likely to get COVID-19 again.

How do you read a Covid antibody test? ›

COVID-19 antibody test results could be:
  1. Positive. A positive test means you have COVID-19 antibodies in your blood, which indicates past infection with the virus. ...
  2. Negative. A negative test means that you have no COVID-19 antibodies, so you probably were not infected with the COVID-19 virus in the past.
27 May 2022

Can you get Covid immediately after recovering? ›

A person can be reinfected with COVID-19 as soon as 28 days after recovering from a previous COVID-19 infection. This means if you had COVID-19, you don't need to be retested for COVID-19 in the 28 days since completing isolation, even if you have symptoms.

What is the importance of vaccination? ›

COVID-19 vaccination helps protect you by creating an antibody response without you having to experience potentially severe illness or post-COVID conditions. Getting sick with COVID-19 can cause severe illness or death, even in children, and we can't reliably predict who will have mild or severe illness.

What are advantages of vaccines? ›

Vaccination is one of the most successful public health interventions in reducing disease spread, preventing complications and even deaths from vaccine preventable diseases. The success of vaccines in reducing disease should not suggest that vaccine preventable diseases are no longer a threat.

Which disease Cannot be prevented by vaccination? ›

There is no vaccine available for osteoporosis. Osteoporosis is an age related problem in which bones becomes very weak due to which even due to sudden or slight jerk leads to bone fracture.

Which COVID vaccine is safest? ›

The Pfizer and Moderna vaccines are strongly recommended as safe and effective at preventing serious illness or death from COVID-19.

How long does the COVID vaccine last? ›

We don't know how long protection lasts for those who are vaccinated. What we do know is that COVID-19 has caused very serious illness and death for a lot of people.

How can I protect my T cells? ›

To strengthen your T cells, we recommend plenty of protein, which can be found in beef, poultry, fish, and eggs. Vegetable foods that contain some protein include beans, quinoa, nuts, and seeds.

Which vaccine is better Johnson and Johnson or Pfizer? ›

Both the Pfizer and J&J vaccines work, and are safe

Both the Pfizer and J&J vaccines are safe and effective in protecting people from severe illness and death from a COVID-19 infection. You can find more clinically-verified information about COVID-19 and vaccines on Discovery's COVID-19 information hub here.

What booster is better Pfizer or Moderna? ›

Pfizer: Is There a “Best” mRNA Vaccine? Both of the mRNA vaccines available in the US are highly effective against severe COVID-19, but recent studies suggest that Moderna's elicits a stronger immune response and might be better at preventing breakthrough infections.

What is the efficacy of Pfizer? ›

The Pfizer BioNTech vaccine against COVID-19 has very high efficacy against severe disease and moderate efficacy against symptomatic SARS-CoV-2 infection.

Is Novavax better than Pfizer vaccine? ›

The study showed Novavax was about 90% effective in preventing COVID infections. That is similar to the efficacy of Moderna (94%) and Pfizer (95%) and better than Johnson & Johnson (66%).

What is the best Covid shot for seniors? ›

U.S. adults aged 65 years or older who have been fully vaccinated with Pfizer-BioNTech or Moderna's COVID-19 vaccines are 94% less likely to be hospitalized with the disease than seniors who were not vaccinated, according to real-world evidence unveiled today by the U.S. Centers for Disease Control and Prevention (CDC) ...

How long does Covid stay in your system? ›

They are typically the most reliable tests for people with or without symptoms. These tests detect viral genetic material, which may stay in your body for up to 90 days after you test positive. Therefore, you should not use a NAAT if you have tested positive in the last 90 days.

Where is Pfizer vaccine made? ›

Where is the Pfizer-BioNTech COVID-19 vaccine made? As of January 2022, the Pfizer-BioNTech COVID-19 vaccine is manufactured between 11 sites across five countries, including the U.S., Germany, Belgium, Ireland, and Croatia, and engages more than 20 suppliers.

How effective is the Omicron vaccine? ›

After a third dose, estimated vaccine effectiveness against Omicron was 61% for symptomatic infection and 95% for severe outcomes.

How long does it take for a booster to take effect? ›

Your body's immune response kicks in almost immediately after a booster dose. It may take around two weeks to reach maximum protection.

How effective is Covid booster? ›

In a large cohort of nursing home residents, receipt of a second mRNA COVID-19 booster dose during circulation of SARS-CoV-2 Omicron subvariants was 74% effective at 60 days against severe COVID-19–related outcomes (including hospitalization or death) and 90% against death alone compared with receipt of a single ...

Does the Covid vaccine prevent Hospitalisation? ›

Among adults aged 50 and older, vaccine effectiveness against hospitalization during BA. 2/BA. 2.12. 1 increased to 80% after a fourth dose, the study found.

Which Covid vaccine is best for over 65? ›

Getting vaccinated prevents severe illness, hospitalizations and death. People 65 and older who received both doses of either Pfizer or Moderna vaccines showed a 94% reduced risk of COVID-19 related hospitalization.

Does vaccine protect against Delta variant? ›

The delta variant is concerning because it's more highly transmissible, but the good news is that the COVID-19 vaccine is still highly protective against getting infected or ending up in a hospital or dying from the infection.

Will Novavax be approved as a booster? ›

Novavax is approved and available for use as a booster in people aged 18 years and over. The TGA provisionally approved Novavax for use as a primary course in Australia on 20 January 2022. The TGA provisionally approved Novavax for use as a booster on 9 July 2022.

Does Novavax cause myocarditis? ›

Myocarditis and pericarditis have been reported with Nuvaxovid (Novavax COVID-19 Vaccine) There have been a small number of cases of myocarditis and pericarditis reported internationally following vaccination with Nuvaxovid.

What are the ingredients in the Novavax vaccine? ›

The Novavax COVID-19 Vaccine, Adjuvanted contains a recombinant form of the SARS-CoV-2 spike protein produced from baculovirus infected Sf9 (fall armyworm) insect cells and Matrix- MTM adjuvant containing saponins derived from the soapbark tree (Quillaja saponaria Molina).

Videos

1. Webinaire du 17 mai 2021: Vaccination contre le COVID-19 et rhumatismes inflammatoires
(Rheumaliga Schweiz)
2. Covid-19 : vaccinations, le fossé !
(TV5MONDE Info)
3. 💉 Quels sont les effets secondaires des vaccins contre le Covid-19 ?
(Figaro Live)
4. Covid-19 et analyse géographique
(TutorielGeo - GIS Center)
5. Tout ce que vous voulez savoir sur la vaccination COVID-19 (9 février 2021)
(Quality Assistance)
6. Modélisation de l'impact des vaccins Covid-19 | 12.08.2021
(ECHO India)

You might also like

Latest Posts

Article information

Author: Wyatt Volkman LLD

Last Updated: 08/15/2022

Views: 5495

Rating: 4.6 / 5 (46 voted)

Reviews: 85% of readers found this page helpful

Author information

Name: Wyatt Volkman LLD

Birthday: 1992-02-16

Address: Suite 851 78549 Lubowitz Well, Wardside, TX 98080-8615

Phone: +67618977178100

Job: Manufacturing Director

Hobby: Running, Mountaineering, Inline skating, Writing, Baton twirling, Computer programming, Stone skipping

Introduction: My name is Wyatt Volkman LLD, I am a handsome, rich, comfortable, lively, zealous, graceful, gifted person who loves writing and wants to share my knowledge and understanding with you.